Articles with public access mandates - francis buadiLearn more
Not available anywhere: 15
What do I need to know about immunoglobulin light chain (AL) amyloidosis?
A Dispenzieri, MA Gertz, F Buadi
Blood reviews 26 (4), 137-154, 2012
Mandates: US National Institutes of Health
A modern primer on light chain amyloidosis in 592 patients with mass spectrometry–verified typing
E Muchtar, MA Gertz, RA Kyle, MQ Lacy, D Dingli, N Leung, FK Buadi, ...
Mayo Clinic Proceedings 94 (3), 472-483, 2019
Mandates: US National Institutes of Health
Presentation and outcomes of localized immunoglobulin light chain amyloidosis: the Mayo Clinic experience
TV Kourelis, RA Kyle, D Dingli, FK Buadi, SK Kumar, MA Gertz, MQ Lacy, ...
Mayo Clinic proceedings 92 (6), 908-917, 2017
Mandates: US National Institutes of Health
Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria
E Muchtar, A Dispenzieri, N Leung, MQ Lacy, FK Buadi, D Dingli, ...
Leukemia 32 (10), 2240-2249, 2018
Mandates: US National Institutes of Health
High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis
A Dispenzieri, MA Gertz, SK Kumar, MQ Lacy, RA Kyle, AK Saenger, ...
Heart 100 (5), 383-388, 2014
Mandates: US National Institutes of Health
A review of POEMS syndrome.
A Dispenzieri, FK Buadi
Oncology (08909091) 27 (12), 2013
Mandates: US National Institutes of Health
Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance
A Lakshman, S Paul, SV Rajkumar, RP Ketterling, PT Greipp, ...
Leukemia 32 (8), 1811-1815, 2018
Mandates: US National Institutes of Health
Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis
E Muchtar, MA Gertz, TV Kourelis, S Sidana, RS Go, MQ Lacy, FK Buadi, ...
Leukemia 34 (4), 1135-1143, 2020
Mandates: US National Institutes of Health
Clinical features and treatment outcomes of patients with necrobiotic xanthogranuloma associated with monoclonal gammopathies
LS Higgins, RS Go, D Dingli, SK Kumar, SV Rajkumar, A Dispenzieri, ...
Clinical Lymphoma Myeloma and Leukemia 16 (8), 447-452, 2016
Mandates: US National Institutes of Health
Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse
S Sidana, N Tandon, A Dispenzieri, MA Gertz, FK Buadi, MQ Lacy, ...
Leukemia 33 (3), 730-738, 2019
Mandates: US National Institutes of Health
Implications of detecting serum monoclonal protein by MASS‐fix following stem cell transplantation in multiple myeloma
JP Abeykoon, DL Murray, I Murray, D Jevremovic, GE Otteson, ...
British journal of haematology 193 (2), 380-385, 2021
Mandates: US National Institutes of Health
A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis
C Heybeli, A Bentall, J Wen, MP Alexander, FK Buadi, FG Cosio, ...
Kidney international 99 (3), 707-715, 2021
Mandates: US National Institutes of Health
Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis
I Vaxman, MH Sidiqi, AS Al Saleh, S Kumar, E Muchtar, A Dispenzieri, ...
Bone Marrow Transplantation 56 (4), 928-935, 2021
Mandates: US National Institutes of Health
Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis
J Cook, WI Gonsalves, MA Gertz, A Visram, R Warsame, MQ Lacy, ...
Bone Marrow Transplantation 57 (6), 1007-1009, 2022
Mandates: US National Institutes of Health
MM-315: Impact of Stratification of Levels of Serum Lactate Dehydrogenase (LDH) at Diagnosis on Overall Survival (OS) in Newly Diagnosed Multiple Myeloma (NDMM)
LA Evans, SK Kumar, A Dispenzieri, FK Buadi, D Dingli, MQ Lacy, ...
Clinical Lymphoma Myeloma and Leukemia 21, S435, 2021
Mandates: US National Institutes of Health
Available somewhere: 202
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
SK Kumar, A Dispenzieri, MQ Lacy, MA Gertz, FK Buadi, S Pandey, ...
Leukemia 28 (5), 1122-1128, 2014
Mandates: US National Institutes of Health
Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements
S Kumar, A Dispenzieri, MQ Lacy, SR Hayman, FK Buadi, C Colby, ...
Journal of Clinical Oncology 30 (9), 989-995, 2012
Mandates: US National Institutes of Health
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
DS Siegel, T Martin, M Wang, R Vij, AJ Jakubowiak, S Lonial, S Trudel, ...
Blood, The Journal of the American Society of Hematology 120 (14), 2817-2825, 2012
Mandates: US National Institutes of Health
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013
JR Mikhael, D Dingli, V Roy, CB Reeder, FK Buadi, SR Hayman, ...
Mayo Clinic Proceedings 88 (4), 360-376, 2013
Mandates: US National Institutes of Health
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma
MQ Lacy, SR Hayman, MA Gertz, A Dispenzieri, F Buadi, S Kumar, ...
Journal of Clinical Oncology 27 (30), 5008-5014, 2009
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program